Home › Funds › Parkman Healthcare Partners LLC › ANRO
Parkman Healthcare Partners LLC position in ANRO
ALTO NEUROSCIENCE INC · Health Care
Parkman Healthcare Partners LLC reported holding 948,863 shares of ANRO (ALTO NEUROSCIENCE INC) in its Q3 2026 13F filing — a position valued at US$24.2M, representing 2.19% of its reported portfolio and ranking #11 among its reported holdings. Parkman Healthcare Partners LLC has disclosed ANRO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's ANRO position evolved
Parkman Healthcare Partners LLC first disclosed a stake in ANRO in Q2 2026 at 429,035 shares (US$11.3M). The position peaked in Q3 2026 at 948,863 shares, worth US$24.2M. Across 2 filings, Parkman Healthcare Partners LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 948,863 shares valued at US$24.2M — an increase of 519,828 shares quarter over quarter.. Notable position changes include a 121% increase in Q3 2026 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 429.04K | $11.32M | New |
| Q3 2026 | 948.86K | $24.22M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANRO and 13F data
ANRO (ALTO NEUROSCIENCE INC) is a Health Care company. 62 other funds we track also report a position in ANRO — the largest reported positions include Alpha Wave Global, LP (US$94.7M), Commodore Capital LP (US$71.9M), EcoR1 Capital, LLC (US$57.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANRO
- Alpha Wave Global, LP 3.71M sh · $94.66M · Q3 2026
- Commodore Capital LP 2.72M sh · $71.87M · Q2 2026
- EcoR1 Capital, LLC 2.23M sh · $56.98M · Q3 2026
- Spruce Street Capital LP 1.68M sh · $42.80M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.61M sh · $42.49M · Q2 2026
- Vivo Capital, LLC 1.36M sh · $34.72M · Q3 2026
- Vestal Point Capital, LP 785.00K sh · $20.72M · Q2 2026
- 72 Investment Holdings, LLC 667.78K sh · $17.62M · Q2 2026
- Affinity Asset Advisors, LLC 643.34K sh · $16.42M · Q3 2026
- Saturn V Capital Management LP 518.11K sh · $13.23M · Q3 2026
- Venrock Adviser, LLC 500.00K sh · $13.20M · Q2 2026
- Integral Health Asset Management, LLC 500.00K sh · $12.77M · Q3 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held ANRO?
Parkman Healthcare Partners LLC has disclosed ANRO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Parkman Healthcare Partners LLC's current position in ANRO?
As of Q3 2026, Parkman Healthcare Partners LLC holds 948.86K shares of ANRO (ALTO NEUROSCIENCE INC), valued at $24.22M, representing 2.19% of its reported portfolio and ranking #11.
Has Parkman Healthcare Partners LLC been buying or selling ANRO?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC increased its position in ANRO. The position peaked in Q3 2026 at 948.86K shares.
Which other funds hold ANRO?
Other major institutional holders of ANRO include Alpha Wave Global, LP, Commodore Capital LP, EcoR1 Capital, LLC, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.